Syövänhoidon vastuualue

Julkaisut 2019 (alustava)
Publications 2019 (preliminary)

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Alminoja A et al. Does Decision-making in End-of-life Care Differ Between Graduating Medical Students and Experienced Physicians?
2 Araque O et al. Selecting the Mammographic-View for the Parenchymal Analysis-Based Breast Cancer Risk Assessment.
3 Aula H et al. Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer.
4 Auvray M et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
5 Bärlund M, Mattson J. Syöpäpotilaan sähköiset seurantamenetelmät.
6 Escala-Garcia M et al. Genome-wide association study of germline variants and breast cancer-specific mortality.
7 Escala-Garcia M et al. Genome-wide association study of germline variants and breast cancer-specific mortality.
8 Forsgård RA et al. Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles.
9 Hackman G et al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
10 Hirvonen OM et al. Assessing the utilization of the decision to implement a palliative goal for the treatment of cancer patients during the last year of life at Helsinki University Hospital: a historic cohort study.
11 Hosio M et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
12 Jansen YJL et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
13 Jääskeläinen A et al. Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.
14 Jääskeläinen A et al. Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer.
15 Kaidar-Person O et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer.
16 Kaikkonen E et al. ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer.
17 Kaikkonen E et al. ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer.
18 Kaikkonen E et al. rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer.
19 Kellokumpu-Lehtinen P-L, Joensuu T. Nya vindar inom behandlingen av prostatacancer.
20 Kellokumpu-Lehtinen PL et al. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer : Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
21 Kokkonen K et al. Cancer Patients' Symptom Burden and Health-related Quality of Life (HRQoL) at Tertiary Cancer Center from 2006 to 2013: A Cross-sectional Study.
22 Koski K et al. Physician self-disclosure and vaccine-critical parents' trust : Preparing medical students for parents' difficult questions.
23 Laaksomaa M et al. AlignRT® and CatalystTM in whole-breast radiotherapy with DIBH: Is IGRT still needed?
24 Lehto J et al. Elämän loppuvaiheen ennakoiva hoitosuunnitelma.
25 Lehto U et al. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer.
26 Lehtomäki K et al. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
27 Leivonen SK et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
28 Loi S et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
29 Mannisto S et al. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
30 Mattila KE et al. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
31 Mavaddat N et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
32 Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
33 Orell H et al. Nutritional Counseling for Head and Neck Cancer Patients Undergoing (Chemo) Radiotherapy-A Prospective Randomized Trial.
34 Partanen A et al. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34.
35 Penttinen H, Sormunen J. Liikunnan vaikutus syövän ehkäisyyn ja sairastuneiden kuolleisuuteen.
36 Penttinen H et al. Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-year Results of the BREX-study.
37 Pertuz S et al. Do Mammographic Systems Affect the Performance of Computerized Parenchymal Analysis?
38 Pertuz S et al. Micro-parenchymal Patterns for Breast Cancer Risk Assessment.
39 Piili R. End-of-Life Decision-Making in Cancer Patients : Attitudes, ethics and background factors among Finnish physicians and medical students.
40 Prusila REI et al. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
41 Rantala HA et al. Predictors of Impaired Survival in Subjects With Long-Term Oxygen Therapy.
42 Reijonen P et al. Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases.
43 Rossi M et al. Optimal selection of optimization bolus thickness in planning of VMAT breast radiotherapy treatments.
44 Saarto T, Lehto J. Palliatiivisen hoidon ja saattohoidon järjestäminen Suomessa - kolmiportainen malli.
45 Salminen V. Uskaltaako potilaasi kertoa sinulle käyttämistään hoidoista?
46 Skyttä T, Mäenpää H. Sädehoidon haittavaikutukset.
47 Skyttä T et al. Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study.
48 Sorigue M et al. Incidence of solid cancer in patients with follicular lymphoma.
49 Soveri LM et al. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
50 Takala L et al. Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
51 Talibov M et al. Workplace Diesel Exhausts and Gasoline Exposure and Risk of Colorectal Cancer in Four Nordic Countries.
52 Terkamo-Moisio A et al. Attitudes of Nurses and the General Public Towards Euthanasia on Individuals with Dementia and Cognitive Impairment.
53 Terävä J et al. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.
54 Tiainen L et al. Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.
55 Tiainen L et al. High baseline Tie1 level predicts poor survival in metastatic breast cancer.
56 Torres GF et al. Morphological Area Gradient: System-independent Dense Tissue Segmentation in Mammography Images.
57 Tuohinen S et al. Syöpäpotilaan sydän - tutkimukset ja hoidon optimointi.
58 Tuohinen SSirkku et al. Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy.
59 Vuorinen R et al. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.
60 Vähämurto P et al. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
61 Winther S et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
62 Wu X et al. Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI).

Julkaisutietokanta 31.12.2020 Publications Data Base 31.12.2020